Rockville, MD, United States of America

Sara Zafar

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Regenxbio Inc.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sara Zafar. Retrieved from https://idiyas.com/inventor/sara-zafar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Sara Zafar

Introduction

Sara Zafar is a prominent inventor based in Rockville, MD (US). She has made significant contributions to the field of biotechnology, particularly in the purification of recombinant Adeno-Associated Virus (rAAV) particles. Her work is crucial for advancements in gene therapy and related applications.

Latest Patents

Sara Zafar holds a patent for "Anion exchange chromatography for recombinant AAV production." This patent outlines methods for the purification of rAAV particles using anion exchange chromatography. This innovative approach enhances the efficiency and effectiveness of rAAV production, which is vital for therapeutic applications.

Career Highlights

Sara is currently employed at Regenxbio Inc., a company known for its pioneering work in gene therapy. Her role involves developing and optimizing methods that contribute to the production of viral vectors used in various therapeutic interventions.

Collaborations

Sara has collaborated with notable colleagues, including Claire G Zhang and Jeffrey Levine. These partnerships have fostered a collaborative environment that enhances research and development efforts within the company.

Conclusion

Sara Zafar's contributions to the field of biotechnology, particularly through her patent on anion exchange chromatography, highlight her innovative spirit and dedication to advancing gene therapy. Her work at Regenxbio Inc. continues to impact the industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…